JP2019524748A - がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 - Google Patents
がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 Download PDFInfo
- Publication number
- JP2019524748A JP2019524748A JP2019502829A JP2019502829A JP2019524748A JP 2019524748 A JP2019524748 A JP 2019524748A JP 2019502829 A JP2019502829 A JP 2019502829A JP 2019502829 A JP2019502829 A JP 2019502829A JP 2019524748 A JP2019524748 A JP 2019524748A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- eribulin
- carcinoma
- tumor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364440P | 2016-07-20 | 2016-07-20 | |
| US62/364,440 | 2016-07-20 | ||
| PCT/JP2017/026212 WO2018016563A1 (en) | 2016-07-20 | 2017-07-20 | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524748A true JP2019524748A (ja) | 2019-09-05 |
| JP2019524748A5 JP2019524748A5 (cg-RX-API-DMAC7.html) | 2020-08-27 |
Family
ID=60993053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502829A Withdrawn JP2019524748A (ja) | 2016-07-20 | 2017-07-20 | がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190282541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3487492A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019524748A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018016563A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US20190046513A1 (en) * | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| JP7169125B2 (ja) * | 2018-08-29 | 2022-11-10 | 株式会社日立製作所 | 質問回答システム、質問回答処理方法、及び質問回答統合システム |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| WO2022048527A1 (zh) * | 2020-09-01 | 2022-03-10 | 深圳微芯生物科技股份有限公司 | 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067543A2 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of Colorado | Treatment of histone deacetylase mediated disorders |
| GEP201706612B (en) * | 2011-09-02 | 2017-02-10 | Novamedica Llc | Methods for the treatment of breast cancer |
| CN105492007A (zh) * | 2013-05-03 | 2016-04-13 | 欣达克斯制药公司 | 癌症治疗方法 |
-
2017
- 2017-07-20 JP JP2019502829A patent/JP2019524748A/ja not_active Withdrawn
- 2017-07-20 WO PCT/JP2017/026212 patent/WO2018016563A1/en not_active Ceased
- 2017-07-20 US US16/318,198 patent/US20190282541A1/en not_active Abandoned
- 2017-07-20 EP EP17831079.3A patent/EP3487492A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190282541A1 (en) | 2019-09-19 |
| WO2018016563A1 (en) | 2018-01-25 |
| EP3487492A1 (en) | 2019-05-29 |
| EP3487492A4 (en) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220110890A1 (en) | Methods for treating cancer | |
| US20080085874A1 (en) | Small molecule potentiator of hormonal therapy for breast cancer | |
| AU2013343425A1 (en) | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases | |
| US20190282541A1 (en) | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer | |
| CN105338977A (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
| WO2016040877A1 (en) | Human dosing of phosphatase inhibitor | |
| CN107982270A (zh) | 治疗乳腺癌的方法 | |
| EP2049121B1 (en) | Compositions for promoting activity of anti-cancer therapies | |
| US20160213669A1 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
| JP2021505571A (ja) | 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法 | |
| BR112020025946A2 (pt) | composições bifuncionais para o tratamento de câncer | |
| WO2022062223A1 (zh) | 金诺芬在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| WO2019113155A1 (en) | Oxabicycloheptanes for treatment of secondary acute myeloid leukemia | |
| US20220047546A1 (en) | Combination cancer therapies | |
| US8501792B2 (en) | Treating cancer with desthiazolyl ritonavir | |
| WO2013138600A1 (en) | Radioprotector compounds | |
| JP2020528052A (ja) | がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用 | |
| WO2013149026A2 (en) | Use of n-(4-((3-(2-amino-4-pyrimidinyl) -2-pyridinyl)oxy)phenyl)-4-(4-methyl -2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer | |
| KR20210073521A (ko) | 암을 치료하기 위한 c-19 스테로이드와의 병용물 | |
| KR20160101027A (ko) | 제약 조합물 | |
| WO2022253748A1 (en) | Combinations for the treatment of hpv | |
| WO2009108361A1 (en) | Methods for treatment and prevention of breast cancer | |
| JP2024538411A (ja) | 心臓保護の方法 | |
| HK40064613A (en) | Methods for treating cancer | |
| KR20240027623A (ko) | 여성형 유방 및/또는 유방통 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200716 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200716 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20210531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210531 |